Drug innovation is delivering highly-effective medicines that significantly improve patient outcomes and, in some cases, are curative of disease. Yet of the 55 medicines that were approved in the US between January 2018 and June 2019, only a handful have been launched in a major market outside the US. Health Technology Assessments (HTA), protracted price negotiations or the fact that smaller developers do not have the resources to overcome challenging market access obstacles are all shaping the competitive landscape for innovative drugs in non-US markets.
Which companies are involved? What products have made the grade and where? When could new competitive threats emerge? For answers turn to the fully-updated and expanded Innovative Drugs: Mapping the Pricing and Reimbursement Landscape. Comprising a detailed report and usable data set in MS Excel™, this comprehensive and granular analysis exposes—at a product level—the pricing, reimbursement and HTA status of innovative drugs in leading non-US markets.
Key facts about this report1) The Analysis Report focuses on the latest developments
A review of the issues and challenges that are impacting product launch.
Summary information of drugs approved by therapy area and company, and sales data for innovative products that have been launched.
- Canada: Patented Medicine Price Review Board;
- France: Haute Autorité de Santé;
- Germany: Gemeinsame Bundesausschuss/Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis;
- UK: National Institute for Health and Care Excellence.
Product level HTA status analysis
- Product overview;
- Regulatory approvals;
- HTA status by country/region.
Products covered in the Analysis Report
The report covers 68 products across a range of therapy areas and conditions including: apalutamide, caplacizumab, delafloxacin, elagolix sodium, fremanezumab, ibalizumab, migalastat, mogamulizumab, risankizumab, rucaparib and semaglutide.
2) The Data Set gives the long view
The Excel Data Set provides a wider perspective and covers 140 products approved in the US and/or the EU between January 2016 and June 2019.
- Products: Product level analysis covers products from Tymlos (abaloparatide; Radius Health), Verzenio/Verzenios (abemaciclib; Eli Lilly) and Calquence (acalabrutinib; AstraZeneca) to Ingrezza (valbenazine; Neurocrine) and Venclexta/Vencyxto (venetoclax; AbbVie/Genentech) and Mepsivii (vestronidase-alfa; Ultragenyx).
- Therapy areas: The 140 products cover over 15 therapy areas—from leading areas such as oncology, anti-infectives and respiratory to rare diseases, gastrointestinal and neurological disorders.
- Conditions: 108 conditions are covered including cancer (various), asthma, dry eye, DMD, Hepatitis C, IBS, psoriasis, Parkinson's disease, epilepsy and diabetes.
- Companies: The products of leading pharmaceutical and biologics companies including AbbVie, Ablynx NV and Acadia Pharmaceuticals to Ultragenyx, Valeant and Vertex Pharmaceuticals.
- Markets: The HTA status, regulatory approvals and sales data in Australia, Canada, France, Germany and the UK.
This report will enable you to…
- Review the pricing, reimbursement and HTA status of each product at the national level
- Profile the therapy areas that are being targeted
- Estimate likely regulatory approval decisions using average timeframes
- Identify products that have been approved but yet not referred for HTA assessment
- Assess the impact of biologic players in the innovative drug space
- Identify innovative products that have only been launched in the US
- Profile innovative therapies in key therapy areas and acute/chronic conditions
What to expect
This report delivers two class-beating analysis resources
1. Analysis Report
An Analysis Report, rich in charts and tables, this detailed analytical report provides clear insights into 68 products approved or reviewed between January 2018 and June 2019.
2. Data Set
Delivered in Microsoft Excel, the Data Set includes all the data on 140 products assessed between January 2016 and June 2019, which can be used for further analysis or incorporated into internal decision support systems.
Why choose FirstWord?
Are you fed up with management reports packed out with uncorroborated content? If this is your experience, then turn to FirstWord because…
- All our information is derived from detailed research
- We deliver hard, verified facts and statistics and don't pack our reports with spurious observations
- Our reports are based on latest research—we don't reuse or recycle content
- We have the expertise to create on-target content that dives deeply into the pressing commercial and market access issues of the day